Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
Open Access
- 13 May 2022
- journal article
- review article
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 17, e11
Abstract
Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.Keywords
This publication has 75 references indexed in Scilit:
- Thromboprophylaxis for Deep Vein Thrombosis and Pulmonary Embolism after Total Joint Arthroplasty in a Low Incidence PopulationKnee Surgery & Related Research, 2013
- Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO‐TEP registryJournal of Thrombosis and Haemostasis, 2012
- Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgeryTherapeutics and Clinical Risk Management, 2012
- Prevention of VTE in Orthopedic Surgery PatientsChest, 2012
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementNew England Journal of Medicine, 2009
- C-reactive protein as a parameter of surgical trauma: CRP response after different types of surgery in 349 hip fracturesActa Orthopaedica, 2006
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass graftsAmerican Heart Journal, 1991